We have assessed during B cell development, the regulation and function of bcl-x, a member of the bcl-2 family of apoptosis regulatory genes. Here we show that Bcl-xr, a product of bd-x, is expressed in pre-B cells but downregulated at the immature and mature stages of B cell development. Bcl-xr but not Bcl-2 is rapidly induced in peripheral B cells upon surface immunoglobulin M (IgM) cross-linking, CD40 signaling, or LPS stimulation. Transgenic mice that overexpressed Bcl-xt within the B cell lineage exhibited marked accumulation of peripheral B cells in lymphoid organs and enhanced survival of developing and mature B cells. B cell survival was further increased by simultaneous expression of bcl-xL and bcl-2 transgenes. These studies demonstrate that Bcl-2 and Bcl-x t are regulated differentially during B cell development and activation of mature B cells. Induction of Bcl-XL after signaling through surface IgM and CD40 appears to provide mature B cells with an additional protective mechanism against apoptotic signals associated with antigen-induced activation and proliferation.
N
'aturally occurring cell death is common during B cell maturation and is accomplished by apoptosis, a morphologically defined process that is widespread during embryogenesis and postnatal development (1) . During B lymphocyte differentiation, it is estimated that as few as one tenth of the daily 3-5 • 107 newly formed B cells is incorporated into the peripheral mature pool (2, 3) . Death appears to be the fate of most B cell precursors with the majority of the cell loss occurring during the transition from large, cytoplasmic ~ chain-producing B cell precursors to small pre-B cells (4, 5) . Because rearrangement of Ig genes is a stochastic process, many B cell precursors fail to complete successful assembly of H and L Ig chains and appear to undergo cell death in the bone marrow (BM) 1 (4, 5) . Later in development, IgM+IgD -immature B cells undergo further selection based on the specificity of their IgM surface receptors. Newly formed B cells that recognize self-antigens are eliminated by apoptosis in the BM or are function~Abbreviations used in this paper: BM, bone marrow; CD40L, CD40 ligand; HIKP, horseradish peroxidase; MCF, mean channel fluorescence.
The first two authors contributed equally to this work. ally inactivated (6) . In the periphery, IgM+IgD + mature B cells can undergo T cell-dependent affinity maturation of their surface antigen receptors after encounter with antigen. This process involves a high rate of somatic mutations in the rearranged Ig genes during antigen-induced proliferation in germinal centers (7). Mature B cells exhibiting high affinity for antigen are preferentially selected whereas those displaying low affinity for antigen die by apoptosis (8, 9) .
The intracellular mechanisms that implement and regulate apoptosis are still poorly understood, but it is thought that cell death is controlled by a genetic program induced within the dying cell (1, (10) (11) (12) . Little is known about the signals that regulate developmental cell death in the B cell lineage. Because the selection of B cell precursors is largely based on the production of functional H and L chain Ig receptors, it has been hypothesized that failure to express a pre-B cell receptor complex leads to cell death (13) (14) (15) . Later in development, signaling through surface IgM is critical for the elimination of B cells activated by self-antigens in the BM, whereas the Fas receptor appears to play a major role in the deletion of activated B cells in the periphery (16) . Beyond those signals that regulate B cell death during development, apoptosis can be induced in B lym-phocytes by a wide variety of stimuli including exposure to cytotoxic drugs, ~-irradiation, glucocorticoids, or withdrawal of growth factors (17) (18) (19) .
The bd-2 protooncogene was the first member of an expanding family of genes that suppresses the apoptotic mechanism (20) , Enforced expression of bd-2 in lymphoid cells prevents or delays apoptosis induced by multiple stimuli (17, 18, 21) . A role for Bcl-2 in the selection ofB lymphocytes was suggested by its pattern of expression during B cell development (22, 23) . Analysis of Bcl-2-deficient mice has demonstrated that Bcl-2 is essential for the maintenance of mature B and T lymphocytes (24, 25) . In addition, Bcl-2 appears to function as a survival signal for positive selection of B cells in germinal centers (8) and for recruitment or maintenance of high affinity memory B cells (26, 27) .
Because mice deficient in Bcl-2 exhibited normal maturation of the B cell lineage (24, 25) , we hypothesized that genes other than bd-2 could function as survival signals during the selection and maturation of B cell precursors. A candidate is bd-x, a member of the bcl-2 family of apoptosisregulatory genes. In the human, two distinct bd-x mRNAs (bcl-xL and bcl-xs) that encode proteins with different biological function were identified (28). In the mouse, bcl-x L is the dominant bcl-x mRNA expressed in embryonic and postnatal tissues including primary lymphoid organs (29, 30 ). Like Bcl-2, the product of bcl-XL localized to mitochondria and perinuclear envelope (29) and can inhibit the apoptotic death of hematopoietic cell lines after growth.
factor withdrawal (28). Analyses of Bcl-x-deficient chimeric mice demonstrated significant alteration in the maturation of B and T cell precursors (31). However, the biological basis for the altered phenotype observed during B cell maturation in bcl-x mutant mice was unclear. In the present studies, we sought to determine the regulation and function of bcl-x during B cell developmenc Our results indicate that the expression of Bcl-XL is essentially limited to pre-B cells, a narrow stage of development characterized by extensive clonal selection. In contrast, its functional homologue, Bcl-2, was downregulated in pre-B cells but expressed in pro-B and mature B cells (23) . Constitutive expression of Bcl-xr promoted accumulation of B cell precursors and mature B cells in the animal and enhanced B cell survival in vitro. Our results demonstrate that Bcl-xL, but not Bcl-2, was upregulated after surface IgM cross-linking, CD40 signaling, or LPS stimulation. Given that Bcl-2 and Bcl-x t were coexpressed in mature B cells after activation, we examined the effect of simultaneous expression of bcl-2 and bcl-xL transgenes. Expression of both Bcl-2 and Bcl-XL led to the enhanced accumulation of B cells in the animal and increased the protection against anti-IgD-induced cell death in vivo. The implications of these findings for physiological pathways of B cell development and survival are discussed.
Materials and Methods
Mice and Injections. C57BL/6 mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Animals used for these studies were between 8 and 12 wk of age unless otherwise indi- insert was microinjected into F 2 hybrid zygotes from (C57BL/6 • SJL/J)F l parents at a concentration of 2-3 ng/txl. After overnight incubation, the eggs that survived to a two-cell stage were transferred to day 0.5 postcoitum pseudopregnant CS-1 females. 3 wk after birth, genomic DNA was prepared from tail tissue and the incorporation of the human bcl-x L transgene was assessed by dot blot analysis or by PCR as previously described (28).
Cell Preparations. B cell-enriched populations were purified from spleens of normal and transgenic mice after in vitro treatment with anti-Thy-l.2 mAb (HO-13.4 clone, a rat IgM antimouse Thy-l.2 mAb) and complement (Cedarlane Laboratories, Ltd., Hornby, ON, Canada). The resulting cell populations were >90% slgM + and <1% CD4 + or CD8 +. To analyze the expression of Bcl-x or Bcl-2 after B cell activation in normal mice, B cell-enriched spleen cells were cultured in RPMI supplemented with 2 mM L-glutamine, 10 -5 M 2-MER, and 10% heat-inactivated FCS (Hyclone Laboratories, Logan, UT) at a concentration of 5 • 106 cells/ml in the presence of different concentrations of affinity-purified F(ab')2 goat anti-mouse IgM polyclonal antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA), 1 b~g/ml recombinant CD40L (38), or 10 ~g/ml LPS (Sigma Chemical Co., St. Louis, MO). At several time points, cells were harvested, washed twice in PBS, and cell lysates prepared as described below. Protein concentration in lysates was determined using a protein detection kit (Pierce Chemical Co., Rockford, IL). For cell viability assays, B cell-enriched spleen cells were cultured in triplicate at a concentration of 106 cells/ml in 96-well microtiter plates. Viable cells were determined at different days by trypan blue exclusion.
Antibodies. FITC-labeled anti-CD4 (clone H129. 19 ) and PEconjugated anti-CD8 (clone 53-6.7) mAbs were purchased from GIBCO BRL Research Laboratories (Gaithersburg, MD). The following antibodies were obtained from PharMingen (San Di-ego, CA): biotinylated anti-CD4 (clone RM-4-5), biotin-and PE-conjugated anti-CD45R (B220) (clone RA3-6B2), PE-conjugated anti-CD24 (HSA) (clone M1/69), PE-and FITC-labeled anti-IgM (clone R6-60.2), FITC-labeled anti-IgD b (clone 217-170), and FITC-labeled anti-CD43 (leukosialin) (clone $7). The streptavidin-RED670 T M reagent was bought from GIBCO-BRL Research Laboratories.
Flow Cytometric Analysis. Single cell suspensions from spleen, LN, and BM were prepared as previously described (39) . Cells (106 ) were incubated with different combinations of antibodies specific for cell surface markers in 100 b~l ofPBS-I% BSA for 30 min on ice and washed twice with PBS-I% BSA. When indicated, streptavidin-IkED670 TM was used for three-color analysis. Cells were analyzed with a FACScan | flow cytometer and a minimum of 3 • 104 events per sample was counted using Lysys II software (Becton Dickinson & Co., Mountain View, CA). Analysis of Bcl-x expression in B cell progenitors was performed by flow cytometry as previously described for Bcl-2 (23), using a mouse IgG3 anti-Bcl-x mAb (40) followed by a biotin-conjugated goat anti-mouse IgG3 (Caltag Laboratories, South San Francisco, CA) and streptavidin-RED670 TM.
Western Blot Analysis. Bcl-x L or Bcl-2 expression was determined by Western blot analysis as previously described (23) . Briefly, proteins (25-100 Ixg/sample) were transferred to nitrocellulose membranes by electrophoresis and then incubated at 4~ overnight with a rabbit anti-Bcl-x polyclonal serum (41) diluted 1/500, 4 C l l , a rat anti-mouse Bcl-2 (42), or with a mouse anti-~-Tubulin antibody (Sigma Chemical Co.) in 1.5% milk-TBS (Tris-but}?red saline) with 30 Ixl of normal goat serum (Sigma Chemical Co.) After five washes in TBS with 0.05% of Tween 20, the membrane was incubated for 1 h at room temperature with horseradish peroxidase (HRP)-conjugated goat antirabbit, goat anti-rat, or goat anti-mouse antibodies (Jackson ImmunoResearch Laboratories, Inc.) diluted 1/50,000 in 1.5% milk-TBS. The reaction was developed by enhanced chemiluminescence using the ECL kit (Amersham Corp., Arlington Heights, IL).
Results

Bd-xL Expression Is Highly Regulated during B Cell Development in Normal
Mice. The expression of Bcl-x proteins was assessed in developing and mature B cells by threecolor flow cytometric analysis using different combinations of antibodies directed to specific surface markers and a mouse anti-Bcl-x mAb (40) . The Bcl-x protein was detected at very low levels in B220a"nCD43 + pro-B cells, upregulated in I g M -B 2 2 0 a~" pre-B cells, and downregulated again in IgM+HSA high immature B cells (Fig. 1 ). Bcl-x was not detected in mature B cells from spleen ( product detected in preparations of developing and mature B cells (Fig. 2) . The 30-kD Bcl-xL protein was expressed in lysates from B220+IgM -B cell precursors but downregulated in more mature B220+IgM + B cells (Fig. 2 ). These results demonstrate that Bcl-xL is the bcl-x product expressed during B cell development. Furthermore, the expression pattern of Bcl-xL is predominantly restricted to pre-B and differs considerably from that previously reported for Bcl-2 (23, 43).
Bcl-x L but Not Bd-2 Is Induced in Mature B Cells after Activation. Resting B cells from peripheral lymphoid tissues
express Bcl-2 but are devoid of Bcl-x protein (23 and Fig.  1 ). To assess whether Bcl-x is regulated during cellular activation, purified populations of splenic B cells were stimulated with purified F(ah)' 2 anti-IgM antibody or LPS, two signals that induce activation and proliferation of B cells (44) . Bcl-xL was clearly upregnlated by 6 h and reached maximum expression at 24 h after surface IgM cross-linking (Fig. 3 A) . The Bcl-x product was detected as a doublet o f 29-31 kD in agreement with previous reports (41, 45) . Induction of Bcl-xt with anti-IgM was dose dependent and reached a plateau with 10 Ixg/ml o f anti-IgM antibody (data not shown). Similarly, stimulation of B cells with the mitogen LPS upregulated Bcl-xL with kinetics comparable to that observed with anti-IgM (Fig. 3 B) . Similarly, signaling through CD40 using recombinant CD40 ligand (CD40L) induced Bcl-x L in splenic B cells (Fig. 3 C) . The level of Bcl-x L induced by CD40 signaling was very similar to that observed after anti-IgM cross-linking (Fig. 3 C) . Induction of Bcl-xL with anti-IgM or CD40L was specific in that both B cell activators failed to modulate Bcl-2 expression (Fig. 3 D) . Thus, peripheral B cells that constitutively produce Bcl-2 can be induced to express Bcl-xL after signaling through surface IgM receptors, stimulation by LPS, or CD40. (Fig. 4 A) , which is known to target genes to lymphoid cells (21, 46) . Three founder mice with 10 btg/ml of F(ab')2 goat anti-mouse IgM polyclonal antibody. Western blot was performed using lysates containing 100, 50, or 25 Ftg of total proteins. As a control, expression of [3-tubulin was also assessed with a mouse antiq3-tubulin antibody followed by goat antimouse serum conjugated to HRP. Densitometry scanning showed that resting splenic B cells from transgenic animals expressed 30% more Bcl-x t than activated B cells from control mice.
Generation of Transgenic Mice Expressing Constitutively
expressing Bcl-xr in lymphoid tissues were identified and used to establish transgenic lines. Each hne was assessed for expression of Bcl-xr protein by Western blot analysis using a polyclonal antibody reactive with the murine and human Bcl-x proteins (41) . One line (bcl-x-87) that exhibited restricted expression o f the bcl-x L transgene to the B cell compartment was further characterized. As shown in Fig. 4 B, Bcl-XL was the only bcl-x product detected by Western blot analysis in the B M and thymus of normal mice. Bcl-x r protein was overexpressed in the B M of bcl-x-87 as compared to the levels o f endogenous Bcl-XL in nontransgenic littermates (Fig. 4 B) . Moreover, Bcl-x L was undetectable in the spleen and lymph nodes of normal mice but it was expressed in bcl-x-87 animals (Fig. 4 B) . The bcl-x L transgene was not detected in purified populations o f T cells and in several nonlymphoid organs including brain, liver, kidney, and lung as determined by comparison to endogenous levels o f B c l -x r observed in control mice (data not shown). The relative levels of Bcl-x L in activated splenic B cells from normal mice and those in resting B cells from transgenic mice were similar when compared by Western blot analysis (Fig. 4 CO. 
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Bcl-x L Protects Immature and Pre-B Cells against Dexamethasone-induced Cell Death.
Pre-B and immature B cells are highly sensitive to treatment with glucocorticoids (23) . To assess the effect of Bcl-xr overexpression in mice, bcl-x-87 transgenic and control httermate animals were treated with 2 mg ofdexamethasone or PBS as a vehicle control, and 48 h later the different B cell populations in the B M were quantiffed by flow cytometry. In accordance with previous results (23), 80% o f I g M -B 2 2 0 auu pre-B and 95% IgM+IgD -immature B cells were preferentially depleted after dexamethasone treatment (Table 1 ). In contrast, pre-B and immature B cells from bcl-x-87 transgenic mice were largely protected (Table 1) . For comparison, parallel experiments were performed with bcl-2 transgenic mice that express Bcl-2 in the B cell lineage (32). As previously reported, overexpression of Bcl-2 protects pre-B and immature B cells against dexamethasone-induced cell death (21, 32, 47) . These results indicate that Bcl-xr can protect developing B cells from glucocorticoid-induced death in a manner indistinguishable from that of Bcl-2 (Table 1) . tors, rapidly begin to die by apoptosis (48) . To assess the effect of bd-xL on B cell survival, spleen cells from bcl-x-87 transgenic and control littermates were cultured in tLPMI medium supplemented with 10% FCS and their viability assessed by trypan blue exclusion from day 1 to 10. There was an improved survival of spleen cells from transgenic mice when compared to spleen cells from control mice (Fig. 5) . After 10 d of culture, only 5% of spleen B cells from normal mice were viable whereas 40% of the B cells from bcl-x-87 mice survived (Fig. 5) . By comparison, we assessed the survival of spleen cells from bd-2 transgenic mice (32) (Fig. 5) . As previously reported, survival was sig- nificantly increased for splenic B cells from bd-2 transgenic mice (21, 32) in a manner similar to that observed in bd-x-87 transgenic mice (Fig. 5) .
Bcl-x L Increases the Survival of Splenic B Cells In Vitro. Splenic B cells, when cultured in vitro without growth fac-
Overexpression of Bcl-x L Protects Pre-B and Immature BM Cells against Dexamethasone (Dex)-induced Cell Death In Vivo
Resting mature B cells constitutively express high levels of Bcl-2 (23) but undetectable levels of Bcl-x L (Figs. 1, 3 , and 4 B). However, after activation, Bcl-xe was induced in splenic B cells whereas Bcl-2 expression remained unchanged (Fig. 3) . To determine whether coexpression of Bcl-2 and Bcl-x t confers an increased resistance to cell death, we compared the capacity of B cells from bd-x-87/ bcI-2 double transgenic mice, bd-2 or bcl-x L single transgenic mice, and control littermates to survive in vitro. The viability of splenic B cells coexpressing bcl-x and bcl-2 transgenes was significantly enhanced as compared to that of single bd-x or bcl-2 transgenic mice (Fig. 5) .
Constitutive Expression of Bcl-x L Leads to Accumulation of Developing and Mature B Cells.
The results shown above indicated that the bd-xL transgene expressed in bd-x-87 mice was functional in pre-B, immature B, and peripheral B cells (Table 1 and Fig. 5 ). We next assessed whether Bclxt overexpression affected B cell homeostasis. In 5-mo-old bcl-x-87 mice, the total number of spleen cells was increased by 108% (283 X 106 vs. 136 X 106 in control mice) and the total number of LN cells was increased by 92% (15.5 • 106 in bd-x-87 mice vs. 7.8 • 106 in control mice; Table 2 ). This increase was due to an accumulation of B220 + cells in all tissues examined since the number of CD4 + and CD8 + T cells remained practically unchanged (Table 2 ). In the BM, the total number of B220 + cells was increased by 158% (18.6 • 106 in bcl-x-87 mice vs. 7.2 • 106 in control mice). Although pre-B and immature B cells were significantly augmented in bcl-x-87 mice, the number of mature IgM+IgD + B cells was particularly increased when compared to control littermates (Table 2) . Given the distinct pattern of expression of Bcl-2 and Bcl-xr during B cell development, we compared the phenotype of bcl-x-87 transgenic animals with that of bd-2 transgenic mice (32). It is interesting to note that the phenotype and accumulation pattern of B cell populations in the BM, LN, and spleen were similar in bcl-x L and bd-2 transgenic animals ( Table 2) .
Because activated B cells can express both Bcl-2 and Bclxt, we tested the possibility of a functional interaction between the two proteins in vivo by mating bcl-x-87 and bd-2 transgenic mice. Co-expression of both bd-x L and bcl-2 transgenes resulted in a significant increase of mature B cells in BM, spleen, and LN as compared to bcl-xL or bcl-2 transgenic animals ( Table 2) . 
Combined Overexpression of Bcl-x L and Bcl-2 Can Protect
Discussion
These studies demonstrate that Bcl-x L is developmentally regulated in the B cell lineage and functions to protect developing and mature B cells from apoptosis. The pattern of Bcl-x L expression is strikingly different from that of Bcl-2, Bcl-x L and Bcl-2 exhibit a distinct expression pattern implying that these two related proteins play different roles in B cell selection and homeostasis. Bcl-2 but not Bcl-xL is highly expressed in large CD43 + early B cell precursors that undergo extensive rearrangements of IgH and IgL chain genes (23) . Thus, Bcl-2 may play a role in the initial stage of B cell maturation when a diverse pool of pre-B cells is generated through IgH and IgL gene recombination (14, 43) . At the end of the pro-B cell stage, Bcl-2 is downmodulated (23) . Most of these B cell precursors will die during the transition to pre-B cells (4, 5) (24, 25) . A very similar pattern of regulated expression for Bcl-XL has been observed during T cell development (55, 56) . The expression of Bcl-x is the highest in C D 4 + C D 8 + thymocytes and downregulated in mature T cells. Thus, the regulation of bcl-x is conserved in both T and B cell lineages.
It is intriguing that Bcl-2 and Bcl-XL, two structurally related proteins that exhibit similar function, are differently regulated during B cell development. A possible explanation is that Bcl-2 and Bcl-xe differ in their ability to counter death signals generated at specific stages during development. Bcl-2 and Bcl-x L share remarkable structural homology and localize to identical intracellular sites, suggesting that they inhibit cell death by a similar biochemical mechanism (29, 57) . However, it has been recently shown that Bcl-2 and Bcl-x t interact differentially with some intracellular targets in vivo (58 and see below). Thus, it is possible that Bcl-2 and Bcl-x L differ in a subtle manner in their functional ability to prevent cell death. Consistent with this possibility is the observation that Bcl-x L is more efficient than Bcl-2 in protecting the immature B cell line WEHI-231 from apoptosis induced by certain chemotherapeutic agents (41) . The antiapoptotic functions of Bcl-2 and Bcl-x r are controlled in part by several interacting proteins (58-60), one of which (Bad) exhibits a differential ability to heterodimerize with Bcl-2 and Bcl-xr (58) . Thus, another possibility is that the expression of the interacting partners of Bcl-2 and Bcl-x r is differentially regulated during B cell development. In this scenario, developmental regulation of Bcl-2 and Bcl-xr could reflect differential requirements for complexes between Bcl-2 or Bcl-xL and their interacting partners to perform specific functions during B cell development.
The signals that govern Bcl-x L expression during B cell development remain to be estabhshed. Because Bcl-x L is upregulated at the pre-B cell stage, it is possible that signaling through the pre-B cell receptor complex is involved in Bcl-x L regulation. Mutant mice lacking a functional pre-B cell receptor complex display a block in B cell development that coincides with the massive loss of precursor B cells in normal mice (13) . Thus, it has been postulated that the pre-B cell receptor complex transduces signals that result in enhanced survival ofpre-B cells (14, 15) . A candidate signal is Bcl-XL since it is upregulated at the pre-B cell stage of development and promotes the survival of developing B cells.
Cellular activation induces intracellular signals such as c-myc that are involved in both proliferation and cell death (61, 62) . In B lymphocytes, cross-hnking with anti-IgM or anti-IgD induces cell proliferation and ultimately cell death (33, 63) . In mature B cells, our studies demonstrate that Bcl-x L is upregulated by cross-linking of IgM receptors and presumably by antigen-IgM interactions. This notion is supported by the recent observation that Bcl-x protein is expressed in proliferating B cells of the germinal center (45) , arguing that Bcl-x L is upregulated during antigendriven B cell activation in vivo. Similarly, Bcl-XL was induced after the CD40-CD40L interaction, a signaling pathway known to dehver survival signals to mature B cells (64) . As with B cells, Bcl-x r can be induced after cellular activation in peripheral T cells (65, 66) . Thus, under physiological situations, induction of Bcl-xr in Bcl-2-positive mature B and T cells may serve as a mechanism to counter more effectively the death signals associated with activation and prohferation (61, 62) . Consistent with this hypothesis is our observation that accumulation of B cells in the animal and B lymphocyte survival in vitro was further increased by simultaneous expression of bd-xL and bd-2 transgenes. Furthermore, combined overexpression of both Bcl-2 and Bclx L in the absence ofT cell costimulatory function protected mature B cells from anti-IgD-induced apoptosis more effectively than either protein alone. This indicates that Bcl-2 and Bcl-x L can function as autonomous survival proteins in B lymphocytes. Under our experimental conditions, coexpression of Bcl-2 and Bcl-xr only partially protected peripheral B cells from anti-igD-induced cell death, presumably because of the powerful cell death signal provided by the high afl%ity anti-IgD antibody (33) . The increased survival of B cell expressing both Bcl-2 and Bcl-xr could be explained by a gene dose effect, implying that resistance to cell death is determined by the relative levels of apoptosisinhibitory proteins. Preliminary results obtained in our laboratory favor this hypothesis since B cells from double bd-2/ bd-2 transgenic mice exhibit in vitro survival greater than heterozygous bd-2 transgenic mice and sim~ilar to that ofbcl-2/bcl-x L transgenic animals (Grillot, D., R. Merino, and G. Nufiez, unpublished observation). Alternatively, the increased survival could be explained by a specific cooperation between Bcl-2 and Bcl-xr. Regardless of the mechanism, our studies suggest that for certain death stimuli, particularly those associated with cellular activation, coexpression of Bcl-2 and Bcl-x L may prove critical in determining the fate of certain populations of B cells.
